On June 11, GSK rose 3.06% in regular trading, trading at $52.92/share, with turnover of $152 million. The stock extended gains as the market continued to positively reassess the company's landmark $10.6 billion acquisition of Nuvalent.

GSK announced a definitive agreement to acquire U.S. biotech firm Nuvalent at $124 per share in cash, representing a 40% premium to Nuvalent's prior closing price. The deal, GSK's largest in over a decade, brings two late-stage lung cancer drugs targeting ALK and ROS1 genetic mutations, with FDA decisions expected later this year. Both candidates have received Breakthrough Therapy and Orphan Drug designations. CEO Luke Miels stated the acquisition will drive revenue growth starting in 2027 and bolster core operating profits during the 2028-2030 patent expiration period for dolutegravir.

Analysts note the deal reflects GSK's urgency to address its patent cliff, with Shingrix declining in the U.S. and key HIV drugs facing generic competition. The broader Pharmacy sector also traded higher, with Pfizer up 2.89%, Merck up 2.79%, and Novo-Nordisk up 2.66%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)